MedTrace Logo

Human Salivary Gland Disposition of Alda-341 in Patients Undergoing Salivary Gland Surgery

NCT04296266 · Status: COMPLETED · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2020-03-05

No results posted yet for this study

Summary

The purpose of this study is determine salivary gland disposition of d-limonene, the primary component in citrus peel and a common dietary supplement.

Salivary gland tissue and saliva will be collected to determine concentration of d-limonene and its metabolites in these tissues.

Conditions

  • Submandibular Gland Tumor
  • Parotid Gland Tumor

Interventions

DRUG

Alda-341

Dietary supplement d-limonene orally administered as a drug.

Sponsors & Collaborators

Principal Investigators

  • Quynh-Thu Le, MD · Stanford University

Study Design

Allocation
NA
Purpose
OTHER
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-02-29
Primary Completion
2017-12-18
Completion
2017-12-21
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04296266 on ClinicalTrials.gov